ATP5MK and neoplasm: It remains to be seen whether or not the fAGP could be validated clinically by using an increased number of samples across tumor types as a predictive biomarker for tumor immunotherapy together with analysis of detailed mechanisms to regulate fucosylation occurred in the AGP molecule during the therapy.